Comparative Pharmacology
Head-to-head clinical analysis: ATMEKSI versus VIAGRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATMEKSI versus VIAGRA.
ATMEKSI vs VIAGRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels in corpus cavernosum, leading to smooth muscle relaxation and blood flow into the penis.
1.5 mg/kg IV every 4 weeks
50 mg orally once as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability. Maximum dosing frequency: once per day.
None Documented
None Documented
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Terminal elimination half-life approximately 4 hours (range 3–5 hours). No significant accumulation with recommended dosing.
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Renal (approximately 80% as metabolites, 20% as unchanged drug in feces), biliary/fecal (about 13% unchanged in feces). Total clearance 41 L/h.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor